# Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

> **NCT04476797** · PHASE1,PHASE2 · TERMINATED · sponsor: **Galera Therapeutics, Inc.** · enrollment: 47 (actual)

## Conditions studied

- SBRT
- NSCLC
- Non-metastatic

## Interventions

- **DRUG:** GC4711 +SBRT
- **DRUG:** Placebo +SBRT

## Key facts

- **NCT ID:** NCT04476797
- **Lead sponsor:** Galera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-18
- **Primary completion:** 2023-11-28
- **Final completion:** 2023-11-28
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to meeting the requirements of a futility analysis
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476797, "Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04476797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*